Rigel Pharmaceuticals
RIGL
104 hedge funds and large institutions have $153M invested in Rigel Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 15 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
20% more call options, than puts
Call options by funds: $6K | Put options by funds: $5K
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
1% more funds holding
Funds holding: 103 → 104 (+1)
46% less capital invested
Capital invested by funds: $282M → $153M (-$129M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.6M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$3.25M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.75M |
| 4 |
BACM
Blue Arrow Capital Management
New York
|
+$1.69M |
| 5 |
BC
Broadfin Capital
New York
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.44M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$1.19M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.11M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$929K |
RIGL Hedge Fund Activity: Q3 2014 in Review
104 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2014, worth a combined $153M — down 46% from $282M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RIGL positions and 15 closed out — a net gain of 1 holder — while 32 added to existing stakes and 25 trimmed.
The largest buyer was Millennium Management, adding an estimated $3.6M. The largest seller was Morgan Stanley, cutting an estimated $3.7M.
- 104 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2014, up from 103 in Q2 2014.
- Funds reported $153M of Rigel Pharmaceuticals stock for Q3 2014, down 46% quarter-over-quarter.
- 16 funds opened new Rigel Pharmaceuticals positions in Q3 2014 and 15 closed out, a net change of +1 holder.
- The largest Rigel Pharmaceuticals buyer in Q3 2014 was Millennium Management, an estimated $3.6M added.
- The largest Rigel Pharmaceuticals seller in Q3 2014 was Morgan Stanley, an estimated $3.7M sold.
Based on aggregated 13F filings for Q3 2014.